Nachrichten zur Johnson & Johnson Aktie

Why Johnson & Johnsons Strong Buy Rating Is Justified (Rating Upgrade)

…

J&J-Backed Medtech Firm HistoSonics Considers US IPO

HistoSonics Inc., a medical device company whose backers include Johnson & Johnson’s venture capital arm, is weighing a US initial…

Spravato sales growth highlights commercial viability of psychedelics, analysts believe

The latest quarterly sales figures for Johnson & Johnson (NYSE:JNJ)’s esketamine nasal spray support the notion that psychedelics can become…

Prediction: This Company Will Have a Trillion-Dollar Market Cap by 2040

The list of companies with market caps of $1 trillion or more remains extremely short. However, theres little doubt that…

These Were the 5 Worst-Performing Stocks in the Dow Jones Industrial Average in 2024

The Dow Jones Industrial Average (DJIA) is a group of 30 U.S. industry leaders. Its often looked at as a…

Up About 62% in a Year, Can Intuitive Surgical Stock Keep Soaring?

Shares of robotic surgery pioneer Intuitive Surgical (NASDAQ: ISRG) have been soaring lately. A preliminary look at sales results from…

Johnson & Johnson Aktie: Kursziel reduziert

New York (www.aktiencheck.de) - Rating-Update: Sanford C. Bernstein hat das Kursziel für die Aktie von Johnson & Johnson (J&J) (ISIN: US4781601046,…

Johnson & Johnson Aktie: Kursziel gekürzt

New York (www.aktiencheck.de) - Rating-Update: Die Analysten von Morgan Stanley haben das Kursziel für Johnson & Johnson (ISIN: US4781601046, WKN: 853260,…

Johnson & Johnson Aktie: Kursziel gesenkt

Charlotte (www.aktiencheck.de) - Rating-Update: Die Analysten von BofA Securities bekräftigen das "neutral"-Rating für die Aktie von Johnson & Johnson (J&J) (ISIN:…

Johnson & Johnson Aktie: Kurzfristiges Aufwärtspotenzial begrenzt

St. Louis (www.aktiencheck.de) - Johnson & Johnson-Aktienanalyse von Stifel: Der Stifel-Analyst Rick Wise hat das Kursziel für die Aktie von Johnson…

This Is 1 of the Healthiest High-Yielding Dividend Stocks Youll Find

Johnson & Johnson (NYSE: JNJ) is an elite dividend stock. The healthcare giant has increased its dividend payment for 62…

Johnson & Johnson optimistisch für 2025 – Wachstum gestützt durch Übernahmen und Krebsmittel

2024 war laut Johnson & Johnson-CEO Joaquin Duato ein Jahr des Wandels, geprägt von starkem Wachstum, einer beschleunigten Pipeline und…

Johnson & Johnson übertrifft Prognosen, Aktienkurs fällt zunächst, erholt sich dann wieder

Frankfurt (www.aktiencheck.de) - Johnson & Johnson übertrifft Prognosen, Aktienkurs fällt zunächst, erholt sich dann wieder - Aktiennews Johnson & Johnson (ISIN:…

S&P 500 hits intraday high, boosted by Netflix, AI investment plan

STORY: Wall Streets main indexes rose Wednesday, with the S&P 500 hitting an intraday record high thanks to strong Netflix…

Johnson & Johnson (JNJ) Q4 2024 Earnings Call Transcript

JNJ earnings call for the period ending December 31, 2024.…

Johnson & Johnson Dips On Q4 Earnings: Heres What The Market Isnt Seeing

…

Johnson & Johnson (JNJ) Q4 2024 Earnings Call Transcript

…

Stocks making the biggest midday moves: Netflix, Johnson & Johnson, Oracle, Ford and more

These are some of the the stocks posting the largest moves in midday trading.…

Johnson & Johnson Aktie: Dividenden-Aristokrat überzeugt

Kulmbach (www.aktiencheck.de) - Johnson & Johnson-Aktienanalyse von "Der Aktionär": Jürgen Dreifürst vom Anlegermagazin "Der Aktionär" nimmt in einer aktuellen Aktienanalyse die…

Johnson & Johnson Tops Q4 EPS Forecasts

Johnson & Johnson surpassed earnings expectations with strong sales, but it faces challenges ahead due to patent expirations.…

Gutes Geschäft mit Krebsmedikamenten verleiht Johnson & Johnson Schub

NEW BRUNSWICK (dpa-AFX) - Der US-Konzern Johnson & Johnson (J&J) hat im vergangenen Jahr die Umsatzeinbußen bei einem seiner wichtigsten…

Gutes Geschäft mit Krebsmedikamenten verleiht Johnson & Johnson Schub

NEW BRUNSWICK (dpa-AFX) - Der US-Konzern Johnson & Johnson (J&J) hat im vergangenen Jahr die Umsatzeinbußen…

Johnson & Johnson: Dividenden-Aristokrat überzeugt

In einem dynamischen Gesundheitsmarkt, der von technologischen Innovationen und steigenden Gesundheitsausgaben geprägt ist, hat Johnson & Johnson seine Widerstandsfähigkeit und…

Johnson & Johnson: Dividenden-Aristokrat überzeugt

In einem dynamischen Gesundheitsmarkt, der von technologischen Innovationen und steigenden Gesundheitsausgaben geprägt ist, hat Johnson & Johnson seine Widerstandsfähigkeit und…

J&J beats quarterly sales and profit estimates on cancer drug sales

Johnson & Johnson , fresh off a $14.6 billion deal to buy neurological drugmaker Intra-Cellular , reported fourth-quarter sales and…

Johnson & Johnson slides as soft sales guidance casts shadow

Johnson & Johnson shares faced pressure on Wednesday as soft sales guidance for the coming year cast a shadow over…

3 High-Yield Dividend ETFs to Buy to Generate Passive Income

Generating income from your investments is a nice thing. After all, youll earn money without punching a clock and answering…

J&Js Depression Drug Spravato Gets FDA Nod for Monotherapy Use

The FDA approves Johnson & Johnsons sNDA for Spravato as a monotherapy for adults with treatment-resistant depression.…

FDA approves Johnson & Johnson’s nasal spray for depression as standalone treatment

Spravato is now the first-ever standalone therapy for treatment-resistant depression, and is on its way to becoming a blockbuster product.…

Johnson & Johnson Aktie: Fokus auf makroökonomische Faktoren

London (www.aktiencheck.de) - Johnson & Johnson-Aktienanalyse von Barclays: Rating und Kursziel Barclays hat das Kursziel für die Aktie von Johnson & Johnson…

These Dividend Stocks Fell Between 1% and 20% in 2024. Heres Why They Are Too Cheap to Ignore and Worth Buying in 2025.

Start Your Mornings Smarter! Wake up with Breakfast news in your inbox every market day. Sign Up For Free » 2024…

Want Decades of Passive Income? 2 Stocks to Buy Now and Hold Forever.

When most of us think of investing in stocks, we think of the potential gains -- or unfortunately, in some…

Can the 8 Worst-Performing Dow Jones Stocks in 2024 Beat the S&P 500 in 2025?

2024 was an excellent year for the major stock market indexes. But the Dow Jones Industrial Average (DJINDICES: ^DJI) had…

Netflix, Procter & Gamble, Johnson & Johnson Report Results In Holiday-Shortened Week

…

3 Super-Safe Dividend Stocks to Buy for 2025 and Beyond

Dividend cuts can be devastating to an income-focused investor. You lose a portion of your passive income, and a dividend…

This Vanguard ETF Has 23% of Its Portfolio Invested in Tech Stocks, but It Can Still Help You Generate Decades of Passive Income

The technology sector has crushed the S&P 500 over the past three, five, and 10 years as leading tech stocks…

Healthy Returns: From Eli Lilly to Amazon, here are the latest health-care deals

Companies from Johnson & Johnson to Eli Lilly, Amazon and Nvidia are announcing health-related deals at the JPMorgan Health Care…

Johnson & Johnsons AAA rating on Credit Watch Negative at S&P following Intra-Cellular Therapies acquisition By Investing.com

Johnson & Johnsons AAA rating on Credit Watch Negative at S&P following Intra-Cellular Therapies acquisition…

dpa-AFX ProFeed